OYST News and Press, Oyster Point Pharma Inc. From 03/30/20

ONSET-2 Phase 3 Top-Line Data Expected by End of Q2 2020              NDA Submission Expected During 2H 2020 PRINCETON, N.J., March 30, 2020 (GLOBE NEWSWIRE) --  Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stag...

Today, we will see why Oyster Point Pharma ( OYST ) is an attractive investment opportunity in 2020. Company overview Oyster Point Pharma is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative treatments targeting ocular surface disea...

Image source: The Motley Fool. Oyster Point Pharma (NASDAQ: OYST) Q4 2019 Earnings Call Feb 27, 2020 , 4:30 p.m. ET Operator Continue reading

Oyster Point Pharma (NASDAQ: OYST ): GAAP EPS of -$1.41 misses by $0.75 . More news on: Oyster Point Pharma, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

ONSET-2 Phase 3 Top-Line Data Expected by End of Q2 2020 Cash and Cash Equivalents of $139.1 million as of December 31, 2019 Conference Call and Webcast Scheduled for 4:30 pm ET PRINCETON, N.J., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinic...

PRINCETON, N.J., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, announced that Jef...

PRINCETON, N.J., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced th...

Oyster Point Pharma ( OYST +4.6% ) is up on average volume in response to positive topline results from a Phase 2 clinical trial, MYSTIC , evaluating lead candidate OC-01 nasal spray for the treatment of dry eye disease. More news on: Oyster Point Pharma, Inc., Kala Pharmaceuticals,...

OC-01 nasal spray showed a statistically significant improvement in Schirmer’s score at Day 84 in both doses tested compared to control   OC-01 nasal spray is a preservative-free, aqueous, nicotinic agonist nasal spray designed to activate the trigeminal parasympathetic pathw...

PRINCETON, N.J., Dec. 23, 2019 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced th...